Table 1.

Noncompartmental pharmacokinetic parameters for hFcRn mouse and monkey studies.

Speciesa	Parameter	t1/2 (day)	Cmax (μg mL−1)	AUCinf (μg mL−1 day)	AUC%Extrap	CL (mL day−1)
hFcRn transgenic mouse1	Trastuzumab	7.03 ± 1.16	71.14 ± 3.95	247.08 ± 18.60	0.6 ± 0.25	0.41 ± 0.03
	Trastuzumab-PFc29	14.07 ± 2.70	79.30 ± 9.48	528.82 ± 101.78	7.7 ± 3.9	0.21 ± 0.04
	Trastuzumab-PFc41	10.90 ± 2.54	67.91 ± 7.60	480.90 ± 60.65	7.0 ± 0.5	0.22 ± 0.02
hFcRn transgenic mouse2	Aflibercept	0.41 ± 0.02	30.55 ± 8.50	15.63 ± 4.06	0.41 ± 0.11	6.40 ± 0.13
	Aflibercept-PFc29	2.10 ± 0.63	45.26 ± 4.42	33.66 ± 4.56	0.40 ± 0.35	2.97 ± 0.09
	Aflibercept-PFc41	1.01 ± 0.03	39.95 ± 5.32	30.33 ± 2.33	0.78 ± 0.14	3.30 ± 1.18
Cyno	Trastuzumab	7.17 ± 0.14	120.38 ± 1.29	881.49 ± 35.68	2.879 ± 0.38	13.64 ± 0.55
	Trastuzumab-YTE	8.84 ± 2.81	130.56 ± 17.43	1001.44 ± 154.20	6.17 ± 4.79	12.27 ± 1.89
	Trastuzumab-LS	8.88 ± 1.17	177.20 ± 10.32	1263.26 ± 42.53	6.05 ± 2.63	9.51 ± 0.32
	Trastuzumab-PFc29	14.34 ± 2.75	228.52 ± 39.46	1966.32 ± 286.39	16.89 ± 5.60	6.24 ± 0.91

t_1/2 terminal half-life (β-phase), C_max maximal concentration, AUC_inf area under the curve from administration to infinity, AUC%_Extrap percentage of the extrapolated area under the curve to the total area under the curve, CL clearance.

^ahFcRn transgenic mouse and Cyno refer to Tg276 mouse (B6.Cg-Fcgrt^tm1Dcr Tg(CAG-FCGRT)276Dcr/DcrJ homozygous) and in cynomolgus monkey, respectively. Dose levels and routes: single i.v. bolus at 5 mg/kg (n = 5) for hFcRn transgenic mouse¹; single i.v. bolus at 4 mg/kg (n = 5) for hFcRn transgenic mouse²; single i.v. infusion at 6 mg/kg (n = 2) for Cyno.